

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5)
09/673049

INTERNATIONAL APPLICATION NO. **PCT/US99/08087**

INTERNATIONAL FILING DATE
13 April 1999

PRIORITY DATE CLAIMED (earliest)
13 April 1998

TITLE OF INVENTION
MULTI-SLICE CEREBRAL BLOOD FLOW IMAGING WITH CONTINUOUS ARTERIAL SPIN LABELING MRI

APPLICANT(S) FOR DO/EO/US
David C. ALSOP

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. has been transmitted by the International Bureau.
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US)
 - d. A translation of the International Application into English (35 U.S.C. 371(c)(2)).
6. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. have been transmitted by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired.
 - d. have not been made and will not be made.
7. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
8. An oath or declaration of the inventor(s) 35 U.S.C. 371(c)(4).
9. A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. A **FIRST** preliminary amendment.
14. A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. A substitute specification.
16. A change of power of attorney and/or address letter.
16. Other items or information:
 - A copy of the Published PCT application by WIPO, under No.WO99/52429 dated October 21, 1999, including the Search Report.
 - A copy of the International Preliminary Examination Report.
 - Associate Power of Attorney.


EXPRESS MAIL Mailing Label No. EL531448662US

Date of Deposit: October 10, 2000 *AC*

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

MAILER Bob Inforzato

SIGNATURE AC

U.S. APPLICATION NO. (known under 37 C.F.R. 1.5) 09/673049	INTERNATIONAL APPLICATION NO. PCT/US99/08087	ATTORNEY DOCKET NUMBER UPN-3617		
<p>17. <input checked="" type="checkbox"/> The following fees are submitted:</p> <p>Basic National Fee (37 CFR 1.492(a)(1)-(5)): Search Report has been prepared by the EPO or JPO..... \$840.00</p> <p>International preliminary examination fee paid to USPTO (37 CFR 1.482) \$670.00</p> <p>No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2))..... \$690.00</p> <p>Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO..... \$ 970.00</p> <p>International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)..... \$96.00</p>		<u>CALCULATIONS</u> <u>PTO USE ONLY</u>		
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$96.00		
Surcharge of \$130.00 for furnishing the oath or declaration later than <u>20</u> <u>30</u> months from the earliest claimed priority date (37 CFR 1.492(e)).		\$		
<input type="checkbox"/> Claims	Number Filed	Number Extra	Rate	
<input checked="" type="checkbox"/> Total claims	8 - 20 =		X \$18.00	\$
<input type="checkbox"/> Independent Claims	1 - 3 =		x \$78.00	\$
<input type="checkbox"/> Multiple dependent claims(s) (if applicable)			+ \$260.00	\$
TOTAL OF ABOVE CALCULATIONS =		\$ 96.00		
Reduction by $\frac{1}{2}$ for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).		\$		
SUBTOTAL =		\$ 96.00		
Processing fee of \$130.00 for furnishing the English translation later the <u>20</u> <u>30</u> months from the earliest claimed priority date (37 CFR 1.492(f)).		+ \$		
TOTAL NATIONAL FEE =		\$ 96.00		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property		+ \$ 40.00		
TOTAL FEES ENCLOSED =		\$136.00		
		Amount to be: refunded \$		
		charged \$		
<p>a. <input checked="" type="checkbox"/> A check in the amount of <u>\$ 136.00</u> to cover the above fee is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. 23-3050 in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner if hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 23-3050. A duplicate copy of this sheet is enclosed.</p>				
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p>				
<p>SEND ALL CORRESPONDENCE TO: Joseph R. Condo Woodcock Washburn Kurtz Mackiewicz & Norris LLP One Liberty Place - 46th Floor Philadelphia, PA 19103 (215) 568-3100</p>				
 SIGNATURE Joseph R. Condo NAME				
42,431 REGISTRATION NUMBER				

09/673049

528 Rec'd PCT/PTO 10 OCT 2000

PCT/US99/08087

7/PRTS

WO 99/52429

MULTI-SLICE CEREBRAL BLOOD FLOW IMAGING WITH
CONTINUOUS ARTERIAL SPIN LABELING MRI

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority from U.S. 5 Provisional Application Serial No. 60/081,506, filed April 13, 1998, the contents of which are hereby incorporated by reference.

GOVERNMENT SUPPORT

This invention was supported by funds from the U.S. 10 Government (National Institutes of Health grants NS01668, P30-MH93880, and P50-NS08803) and the U.S. Government may therefore have certain rights in the invention.

BACKGROUND OF THE INVENTION

Field of the Invention

15 The present invention relates to a technique for imaging regional cerebral blood flow (CBF) noninvasively using MRI with radio frequency arterial spin labeling and, more particularly, to a labeling technique which permits extension of this technique to a multi-slice examination.

20 **Description of the Prior Art**

The measurement of regional cerebral blood flow (CBF) is known to provide useful information both about cerebrovascular sufficiency and about regional brain metabolism because resting CBF and tissue metabolism are often strongly 25 coupled. CBF imaging with Single Photon Computed Tomography

- 2 -

(SPECT), Positron Emission Tomography (PET) and Xenon enhanced CT have been used to evaluate a multitude of cerebral disorders including stroke, dementia, epilepsy, trauma and neoplasms. PET imaging of CBF has also been an important tool for mapping 5 task induced brain activity in normal and pathologic states. However, for most central nervous system disorders, Magnetic Resonance Imaging(MRI) provides the greatest sensitivity to structural abnormalities. A robust MRI based method for clinical imaging of CBF would allow both an anatomical and a 10 functional assessment within the same examination. In addition to providing direct structure-function correlation, the higher spatial resolution of MRI as compared to nuclear medicine methods will lead to better image quality.

MRI of CBF can be performed either with 15 intravascular contrast agents or by Arterial Spin Labeling (ASL). As known to those skilled in the art, instead of using an exogenous tracer, ASL electromagnetically labels water proton spins in the feeding arteries before they flow into the tissue. ASL is attractive since it can reduce the risk, 20 complexity, and cost of a study. It is also more readily quantified and repeated than contrast agent methods.

Arterial Spin Labeling (ASL) techniques can be crudely divided into pulsed inversion techniques, such as EPISTAR, FAIR and other variants, and techniques which employ 25 continuous arterial spin labeling (CASL). CASL produces more than twice the signal of pulsed techniques. Unfortunately, with both methods, multi-slice imaging is complicated by effects of the electromagnetic labeling on the image intensity, as well as the relatively long time required for blood to flow 30 from the arteries into the thick slab of tissue to be imaged.

The ASL approach to MRI of CBF offers the potential for completely non-invasive, quantitative imaging of an important physiologic and diagnostic quantity; however, practical implementations of ASL in humans have typically 35 suffered from systematic errors and artifacts which can only be corrected one slice at a time and which have thus limited its applicability. Recently, the use of fast imaging methods

and an increased understanding of the factors affecting quantification of CBF have led to the acquisition of single-slice CBF images of good quality such that clinical and research applications can be explored. Unfortunately, most 5 applications require greater slice coverage but the serial acquisition of many slices can be prohibitively time consuming. However, improved Radio Frequency (RF) pulse shapes and sequence design has made multi-slice pulsed ASL techniques feasible and multi-slice perfusion imaging more practical for 10 diagnosis.

Accordingly, a method is desired which makes possible multi-slice imaging of CBF with good signal-to-noise ratio and arbitrary angles between imaging and labeling planes. The present invention is designed to meet this need in the art.

15

SUMMARY OF THE INVENTION

The present invention relates to a method for generating two sets of images which are identical except for the effects of blood flowing into the imaged slices. Subtraction of the two images can provide images of blood 20 flowing in large vessels, sometimes referred to as angiograms, or perfusion, sometimes referred to as tissue specific blood flow, depending upon the timing of the imaging sequence. In particular, the present invention relates to the use of amplitude modulated RF irradiation prior to the acquisition of 25 one set of images, hereafter referred to as the control images, and the use of unmodulated RF irradiation prior to the acquisition of the second set of images, hereafter referred to as the labeled images. It is known in the prior art that constant RF irradiation, in combination with a magnetic field 30 gradient, can change the MR signal of flowing blood from positive to negative. The present invention employs the amplitude modulated RF irradiation prior to the control image acquisition to mimic all the blood flow unrelated effects of the constant RF irradiation while leaving the blood signal 35 positive. While prior art techniques for the control image were only effective in a single thin slice at a particular

angular orientation or required a second RF coil, the amplitude modulated control approach of the invention is effective for any number, orientation, and thickness of slices.

In particular, the invention relates to a method for 5 imaging blood flow into a sample such as a tissue sample or a large blood vessel. A preferred embodiment of the inventive method comprises the steps of:

10 perturbing arterial spins of blood flowing into the sample by applying a constant RF irradiation together with a magnetic field gradient;

15 acquiring a first image of the sample;

applying amplitude modulated RF irradiation with a magnetic field gradient which, together, mimic the effects of constant RF radiation unrelated to blood flow;

20 15 acquiring a second image of the sample; and

generating a difference signal based on the first image and the second image that represents a blood flow image of blood flowing into the sample.

In a preferred embodiment of the invention, the 20 first image is acquired after a delay period by detecting a magnetic resonance signal reflected off of the sample. The delay period is set either to allow the blood having the perturbed spins to flow into the tissue before the images are captured (i.e., to capture a perfusion image), or to ensure 25 that the images are captured while the blood is still in the blood vessel (i.e., to capture a large vessel blood flow image). The second image is acquired in a similar fashion shortly after the amplitude modulated RF irradiation is applied. The analog magnetic resonance signals are preferably 30 digitized and processed to measure blood flow via known techniques.

BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing and other novel features and advantages of the invention will become more apparent and more 35 readily appreciated by those skilled in the art after consideration of the following description in conjunction with the associated drawings, of which:

Figure 1A illustrates a single slice experiment in which the control labeled images are acquired with labeling applied at an equal distance distal to the slice (solid line) to compensate for the spatially dependent off resonance effects.

Figure 1B illustrates the amplitude modulated irradiation technique of the invention whereby two inversion planes are created close to the original labeling plane.

Figure 2 illustrates a pulse sequence timing diagram for the entire sequence used to amplitude modulate the RF pulse in accordance with the method of the invention.

Figure 3 illustrates the percent difference between labeling and control images in a phantom as a function of frequency.

Figure 4 illustrates coronal images acquired in a human study with the label and control respectively placed at the ponto-medullary junction and 2 cm above the brain as indicated on the sagittal T1 images on the left of the figure.

Figure 5 illustrates a plot of the residual subtraction errors caused by imperfect matching of off-resonance saturation.

Figure 6 illustrates the efficiency of spin labeling with amplitude modulated control as a function of modulation frequency relative to a single slice labeling.

Figure 7 illustrates echoplanar images from eight axial slices (top row) used to generate CBF sensitive images (second row) as well as acquired T1 maps (third row) used to generate quantitative images of CBF (bottom row).

DETAILED DESCRIPTION OF THE PRESENTLY PREFERRED EMBODIMENTS

A preferred embodiment of the invention will now be described in detail with reference to Figures 1-7. Those skilled in the art will appreciate that the description given herein with respect to those figures is for exemplary purposes only and is not intended in any way to limit the scope of the invention. All questions regarding the scope of the invention may be resolved by referring to the appended claims.

MATERIALS AND METHODSAmplitude Modulated Control

Continuous application of off resonance RF power causes saturation of image intensity due to the finite width 5 of the water line and the transfer of saturated magnetization from water molecules adjacent to macromolecules, which have much broader lines. The off-resonance inversion power applied in CASL usually causes such saturation and its presence complicates CBF imaging since the off-resonance effects may be 10 large compared to the effects of blood flow. An approach to eliminating this saturation is the use of a second small RF coil for labeling that is far enough from the imaged slice that the off-resonance power is negligible. This method has been previously used successfully to obtain multi-slice CBF images 15 in a rat brain but it requires special RF hardware and a favorable geometry for the labeling which limits its applicability. The alternative is to control for the saturation. Since ASL CBF imaging relies on the subtraction of the labeled image from a reference image obtained without 20 labeling, achieving equal off-resonance saturation in the reference image will control for the saturation effect.

Figure 1 illustrates control methods for CASL imaging of CBF. RF irradiation used to label inflowing blood as it crosses the labeling plane (dashed line) also causes 25 direct effects on image intensity that vary with distance from the labeling plane. The established method of controlling for off resonance saturation with a single RF coil was to apply an inversion distal to the slice during the control image, as illustrated in Figure 1A. Figure 1A illustrates a single slice 30 experiment in which the control labeled images are acquired with labeling applied at an equal distance distal to the slice (solid line) to compensate for the spatially dependent off resonance effects. If there are no significant background magnetic field gradients in the sample (e.g., the tissue or 35 blood vessel), the off-resonance saturation is symmetric in frequency, and the labeling and control inversion are parallel to and equidistant to the image slice, then the control image

will experience equal off-resonance saturation. However, the requirement that the labeling and control inversion planes be equidistant to and parallel to the image slice restricts the geometry of ASL CBF images and is not readily extended to a 5 multi-slice examination. To overcome these limitations, an alternative control irradiation which mimics the frequency dependent off-resonance effects of the labeling irradiation is required.

Thus, in the method of the invention, applying an 10 amplitude modulated form of the labeling RF irradiation for the control was evaluated. In particular, it was observed that when a constant RF irradiation at a fixed frequency, f_0 , is multiplied by a sine wave at frequency f_1 , the signal produced is mathematically identical to continuous irradiation at two 15 different frequencies, $f_0 + f_1$ and $f_0 - f_1$. If applied in the presence of a magnetic field gradient, each would separately perturb, such as by adiabatic inversion, inflowing arterial spins. When performed simultaneously, the combined effect is complicated because the equations governing spin evolution are 20 not linear in the applied RF. However, the nature of resonance suggests that the effect of the first inversion on spins located near the second inversion plane should be small as long as the frequency spacing between the planes is large. In this case, the spins will be inverted twice after flowing through 25 the two inversion planes, as illustrated in Figure 1B. In Figure 1B, the amplitude modulated irradiation creates two inversion planes (solid lines) close to the original labeling plane. Ideally, the inflowing spins are inverted twice as they flow through the planes producing no net effect on arterial 30 labeling while the spatially dependent off resonance effects of the RF irradiation are precisely reproduced. Double inversion produces no net effect, so spins would not be labeled by the amplitude modulated control. Because the average power and center frequency of the amplitude modulated control are 35 identical to the labeling RF irradiation, the off-resonance effects of the control are nearly identical to those of the labeling.

The performance of amplitude modulation of the RF irradiation as a control will depend on how perfectly the spins are doubly inverted, and on how well the off-resonance saturation of the labeling irradiation is matched. If the 5 spins are partially labeled by the amplitude modulated control, then the difference between the labeled and control images will decrease. This can be thought of as a loss of efficiency for labeling of blood flow. If the control does not perfectly match the off-resonance saturation of the labeling, then a 10 difference between the images will occur even in the absence of blood flow. This would represent a systematic error in the blood flow measurement. Both of these properties of the control were assessed experimentally as described below.

Imaging

15 All studies using the techniques of the invention were performed on a 1.5 Tesla GE SIGNA clinical scanner equipped with a prototype gradient system for echoplanar imaging. Gradient echo echoplanar images were obtained using a field of view of 24 cm along the frequency encoding direction 20 and 15 cm for the phase direction and an acquisition matrix of 64 x 40. An acquisition bandwidth of \pm 62.5 kHz allowed an effective TE of 22 ms and an image acquisition time of 45 ms. Multi-slice image acquisition was performed without pausing 25 between slices so that 8 slices could be acquired in less than 400 ms. Slice thickness ranged between 6 and 10 mm and interslice gaps of 2 mm between slices were used to minimize potential interference between slices.

Spin labeling was performed for single slice CBF imaging except for the amplitude modulated control and the 30 acquisition of more than one slice. Specifically, a TR of 4s, temporal interleaving of labeled and control images, and a post-labeling delay were employed. The post-labeling delay reduced the sensitivity of the CBF image to the transit time from the labeling plane, attenuated the signal from 35 intraluminal arterial spins, and decreased the off-resonance saturation of the image intensity by the labeling RF. The post-labeling delay also allows time for all of the labeled

blood to enter the tissue before imaging so that saturation of labeled spins by the imaging excitation pulses need not be considered. The duration of the labeling irradiation was determined by the post-labeling delay, the imaging time and TR.

5 For a post-labeling delay of 1.2s, the irradiation was applied for 2.3s. A pulse sequence timing diagram for the entire sequence is shown in Figure 2. In the timing diagram of Figure 2, labeling RF signals and gradients are applied during the labeling period. Rapid gradient echo echoplanar imaging was
10 used to acquire images from the 8 slices.

In addition to the CBF scan, multi-slice versions of the conventional echoplanar T1 mapping scans were performed. The T1 maps are necessary for quantification of the CBF images. Unlike in the single-slice implementation, it was necessary to
15 leave the labeling gradient on during T1 mapping to accurately measure the T1 shortening effect of the off-resonance saturation. In all other ways the protocol was identical. The entire T1 mapping protocol required 3 minutes for all slices.

All raw echo amplitudes were saved and transferred
20 to a workstation for reconstructing the images. A correction for image distortion and alternate k-space line errors was performed on each image using data acquired during a phase encoded reference scan. As known to those skilled in the art, the correction for distortion involves the measurement of
25 magnetic field nonuniformity throughout the image. A side-effect of this correction is that image regions where insufficient MR signal is present to accurately measure the magnetic field are set to zero. The magnitude images were then averaged and the CBF weighted images were calculated by
30 subtraction of labeled images from the control images. An algorithm to remove subtle motion artifacts from the images was performed on the individual images prior to averaging for more accurate evaluation of the performance of the control.

Phantom Studies

35 Prior to evaluation in human subjects, the sequence was tested and calibrated on a uniform phantom consisting of 2% agarose by weight in distilled H₂O. Such a phantom with

significant magnetization transfer was necessary to fully test the control. The magnetization transfer properties of agarose are well studied but considerably different from most human tissues. Since it was desired that the control would be 5 accurate across a wide range of tissue types, the agarose phantom was selected since it served as an extreme case.

The phantom consisted of a cylindrical plastic container, 10 cm in diameter and 20 cm long, filled with the gelatinous mixture. The phantom was placed in the standard 10 head coil of the scanner with the axis parallel to the axis of the magnet. Single-slice images employing the CBF labeling strategy were acquired in a plane perpendicular to the axis of the phantom. A labeling RF irradiation of 35 mG and a labeling gradient of 0.25 G/cm applied along the frequency direction of 15 the image were used. Images were acquired with amplitude modulation frequencies of 125, 250 and 500 Hz. Off-resonance saturation was analyzed by averaging the images across the phase direction so that plots of off-resonance saturation as a function of frequency could be generated.

20 During evaluation of the sequence, it was found that weak saturation of signal at the labeling plane occurred even when the RF amplitude was set to zero in software. This indicated that a small amount of RF was leaking past the modulator. The saturation could be eliminated by setting the 25 RF amplitude to a small negative value corresponding to 2% of the RF amplitude used for labeling. A constant value of 2% of the signal amplitude was subtracted from the software values of all of the labeling related RF amplitudes to compensate for this carrier leakage. Failure to correct for this leakage 30 would cause systematic error in the CBF measurement. Since the leakage is a subject independent phenomenon, it can be calibrated with phantom measurements and need never be measured in subjects.

Human Studies

35 Three different human studies were performed. In one study, the amplitude modulated control method was tested for systematic offset due to imperfect matching of the

- 11 -

off-resonance saturation for label and control. Two subjects were scanned with a control modulation frequency of 250 Hz, an RF irradiation amplitude of 35 mG, a post-labeling delay of 1.2 s, and a 0.25 G/cm labeling gradient. Images from eight 8 mm thick slices were obtained from both subjects when the labeling was applied to the carotid and vertebral arteries at the ponto-medullary junction, to generate CBF images, and also when the labeling was applied distal to the imaging slice at the top of the brain, which should produce no flow-related signal in the absence of systematic error. One of the subjects was scanned in the axial plane while the other was scanned in the coronal plane to emphasize the flexibility of slice geometry made possible by the amplitude modulated control technique of the invention.

In a second study, the efficiency of the multi-slice CBF measurement was compared with the single slice method. CBF images were acquired in a single axial slice through the basal ganglia and thalamus in nine subjects. Images were acquired with both the single slice method, where the control is labeling distal to the slice, and the multi-slice method. All subjects were studied with a 0.25 G/cm labeling gradient, an RF irradiation amplitude of 35mG, a control modulation frequency of 250 Hz, a post-labeling delay of 1.2 s, and a labeling plane offset of between 4 and 8 cm from the slice. Between 15 and 45 difference images were averaged for each subject. In three of these subjects the single slice and multi-slice methods were also compared at RF amplitudes of 30 and 20 mG. In three other subjects, the methods were also compared with modulation frequencies of 62.5 Hz, 100 Hz, 125Hz, 200 Hz and 500 Hz.

In the final human study, multi-slice CBF images and T1 maps were obtained with 250 Hz modulation and 35 mG RF amplitude in four subjects for quantitative analysis of CBF using prior art methods. The entire CBF imaging sequence required 9 minutes including T1 mapping and 45 averages of tagged and control images. The multi-slice labeling efficiency measured in the first study was used for quantification.

RESULTSPhantom Study

Matching of frequency dependent off-resonance saturation effects between the labeling and amplitude modulated control was excellent at all three frequencies, as shown in Figure 3, where the percent difference between labeling and control images in the phantom is shown as a function of frequency. Though both types of irradiation produced off-resonance saturation of greater than 15% of the unsaturated signal, the difference between the two was less than 0.1% except very close to the labeling plane. The frequency at which the difference between the labeled and control frequencies became significant was smaller for lower frequency amplitude modulation. This suggests that labeling can be performed closer to the most inferior region to be imaged when a slower amplitude modulation is used.

Human Studies

Excellent matching between the labeling and control off-resonance saturation in the phantom was also reproduced in the *in vivo* studies. Figure 4 shows the coronal images acquired with label and control placed at the ponto-medullary junction and 2 cm above the brain as indicated on the sagittal T1 images on the left of the figure. Multi-slice difference images acquired with the proximal labeling (top right) demonstrate signal from CBF. Images acquired with the distal labeling (bottom right) show no significant signal. In other words, while the scans with the ponto-medullary junction label show strong perfusion signal in all distal regions of the brain, those with the label above the brain show no significant signal.

To further quantify residual subtraction errors caused by imperfect matching of off-resonance saturation, the image intensity was averaged across the slice and phase directions, similar to the phantom analysis, and the results were plotted in Figure 5. In Figure 5, the average difference signal was obtained by averaging the images of Figure 3 across the anterior-posterior and right-left directions. Distance

from the labeling plane was converted into frequency offset for plotting. As shown, proximal labeling at the ponto-medullary junction produced a small but very significant change in the image intensity due to CBF, while distal labeling above the 5 brain produced no significant signal change consistent with negligible off-resonance errors for offset frequencies above 2 kHz.

While perfusion produces a signal change of under one percent in the proximal labeled scans, residual subtraction 10 error for frequencies above 2 kHz as measured by the distal labeled scans is consistent with noise and is always less than 0.05 percent. The average of the subtraction signal across frequency from 2 to 10 kHz is less than 0.007 percent of the control image intensity. Since the CBF images were acquired 15 in a plane perpendicular to the labeling plane, their uniformity is also a direct indicator of the accuracy of the control. Errors in subtraction are apparent in the perfusion signal of Figure 5 very near the labeling plane at offset frequencies below 2 kHz. The subtraction error produces a 20 shift to a negative signal consistent with the phantom results of Figure 3.

The mean efficiency ratio of the multi-slice and single slice methods was $61.6\% \pm 6.7\%$ across the nine subjects when a modulation frequency of 250 Hz was used. This 25 efficiency was found to drop rapidly when the amplitude of the RF was lowered; the efficiency at 30 mG was 58% and at 20 mG it was only 35%. As shown in Figure 6, the efficiency of spin labeling with amplitude modulated control as a function of modulation frequency relative to a single slice labeling with 30 36 mG amplitude irradiation improved to 75% when the modulation frequency was lowered. This suggests that a modulation frequency of 62.5 Hz is more desirable than 250 Hz.

Quantification of the CBF images was next performed using prior art methods for single slice imaging. The average 35 of the labeled images was first subtracted from the average of the control images and then divided by the intensity of an image obtained in the absence of off resonance saturation.

- 14 -

This ratio was then multiplied by a calibration factor which is a function of the calculated T1 images, the transit times to the tissue from the labeling plane, and the post-labeling delay for each slice. Because the transit time to the tissue 5 was not measured, an assumed value of 1.5 s was employed for quantification. The long post-labeling delay minimized the sensitivity of the calibration factor to differences between the assumed and actual transit time. The images were corrected for inefficiency of labeling by dividing by an efficiency of 10 58.5%. This value was based on an efficiency of 95% for the single slice experiment and the measured ratio of multi-slice to single slice efficiency of 61.6%. Calculated images from one of the subjects are displayed in Figure 7. In Figure 7, echoplanar images from eight axial slices (top row) were used 15 to generate CBF sensitive images (second row). Using the T1 maps also acquired (third row), quantitative images of CBF were generated (bottom row).

These images are not corrected for spatial variations in the blood-brain partition coefficient. 20 Quantitative CBF values were derived by segmenting the tissue into gray and white matter based on the T1 maps and using a partition coefficient of 0.98 for gray matter and 0.82 for white matter. The measured CBF values are consistent with values for quantitative cerebral blood flow ($\text{ml } 100 \text{ g}^{-1} \text{ min}^{-1}$) 25 obtained previously using single slice methods and with other measurements of CBF, as represented for four normal volunteers in Table 1.

Table 1

Subject	Age	Sex	Gray Matter	White Matter	Mean
1	24	M	70.5	27.1	53.7
2	25	M	71.4	28.5	54.8
5	32	M	61.7	32.5	50.4
4	21	F	85.9	49.7	71.9
Mean	25.5 ± 5		72.4 ± 10	34.5 ± 10	57.7 ± 10

DISCUSSION

The invention relates to a method for multi-slice CBF imaging using CASL with an amplitude modulated control. This control strategy is both highly effective at controlling for off-resonance effects and efficient at doubly inverting inflowing spins, thus retaining the signal advantages of CASL versus pulsed ASL techniques. The method is readily implemented using standard hardware, is effective in both gray and white matter, and allows flexible selection of the imaging and labeling planes. Because the control method is applied at the same location as the labeling and gives equal effect across a wide range of frequencies, there should be no errors associated with static magnetic field inhomogeneity or asymmetry in the off-resonance spectrum. The labeling method is therefore highly desirable even for single-slice CBF imaging applications. This approach should also be applicable to blood flow measurements in organs other than the brain. Also, although the above studies were carried out in eight slices, the number of slices is limited only by the image acquisition time and T1 of blood and tissue.

The highest efficiency was measured for the lowest modulation frequency in the study, 62.5 Hz, which was contrary to the inventor's expectation that the two inversion planes would start to interfere as they became closer. The inventor

has implemented numerical simulations of the control using methods similar to those published for single slice labeling. These simulations suggest that inefficiency results primarily from non-linear interactions between the two inversion planes 5 rather than T1 decay between the two planes.

The use of gradient echo echoplanar imaging with a moderately long TE in this study caused signal loss in parts of the inferior frontal and temporal lobes because of nonuniform magnetic fields near bones and sinuses. Spin echo 10 echoplanar was avoided because it would have increased the duration of image acquisition. Fractional k-space acquisition could have enabled much shorter effective TE gradient echo or spin echo echoplanar images with comparable or shorter acquisition times to the sequence. If necessary for image 15 speed or quality, other imaging methods such as interleaved echoplanar or RARE might be employed as long as they do not unacceptably increase the motion artifact.

Spin labeled perfusion images clearly reflect CBF and its spatial and temporal variation but further work is 20 required to test and validate the quantitative values obtained with the technique of the invention.

Those skilled in the art will appreciate that the extension of CASL CBF imaging to a multi-slice modality in accordance with the techniques of the invention overcomes a 25 major obstacle to clinical applications. The techniques of the invention have already been successfully applied in patients with cerebrovascular disease. CBF measurements using this approach are also likely to provide a sensitive and quantitative measure of cerebrovascular reserve when carried 30 out in conjunction with acetazolamide administration or CO₂ inhalation. Numerous other potential clinical applications can be envisioned, including the differential diagnosis of dementing disorders and cerebral neoplasms. In addition, quantitative CBF measurements have applications to clinical and 35 basic neuroscience, for imaging regional CBF changes during sensorimotor or cognitive tasks or following pharmacological challenges, and for population-based studies of changes in

regional CBF and metabolism.

Those skilled in the art will appreciate that numerous other modifications to the invention are possible within the scope of the invention. Accordingly, the scope of the invention is not intended to be limited to the preferred embodiments described above, but only by any appended claims.

CLAIMS**I CLAIM:**

1. A method for imaging blood flow, comprising the steps of:
 - 5 perturbing arterial spins of blood flowing into the sample by applying a constant RF irradiation together with a magnetic field gradient;
 - acquiring a first image of the sample;
 - applying amplitude modulated RF irradiation with a
 - 10 magnetic field gradient which, together, mimic the effects of constant RF radiation unrelated to blood flow;
 - acquiring a second image of the sample; and
 - generating a difference signal based on the first
 - image and the second image that represents a blood flow image
 - 15 of blood flowing into the sample.
2. The method of claim 1, comprising the further step of waiting a transit delay period before acquiring the first image of the sample.
3. The method of claim 2, comprising the further step of determining a duration of the transit delay period so as to permit the blood having perturbed arterial spins to flow into a tissue, thus causing the blood flow image to be representative of perfusion.
4. The method of claim 2, comprising the further step of determining a duration of the transit delay period so as to ensure that blood having perturbed arterial spins remains in a blood vessel of the sample, thus causing the blood flow image to be representative of large vessel blood flow.
5. The method of claim 1, wherein the step of acquiring the first image and the step of acquiring the second image each comprises detecting a magnetic resonance signal reflected off of the sample.

6. The method of claim 5, wherein the magnetic resonance signal is an analog signal, the method further comprising the steps of:

digitizing the magnetic resonance signal to form a digital magnetic resonance signal; and

measuring the blood flow into the sample based on the digital magnetic resonance signal.

7. The method of claim 1, wherein the step of applying
amplitude modulated RF irradiation comprises applying amplitude
10 modulated RF irradiation having a modulation frequency in the
range of about 62.5 Hz to about 500 Hz.

8. The method of claim 7, wherein the step of applying amplitude modulated RF irradiation comprises applying amplitude modulated RF irradiation having a modulation frequency of
15 about 62.5 Hz.




FIG. 1A




FIG. 1B




FIGURE 2




FIGURE 3

591673349

WO 99/52429

PCT/US99/08087

4/7






FIG.4

**FIGURE 5**

**FIGURE 6**




FIG. 7

DOCKET NO.: UPN-3617

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

David C. ALSOP

International Patent

Application No. PCT/US99/08087

International Filing Date: 13 April 1999

**For: MUTLI-SLICE CEREBRAL BLOOD
FLOW IMAGING WITH CONTINUOUS
ARTERIAL SPIN LABELING MRI**

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; and

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a

Utility Patent Design Patent

is sought on the invention, whose title appears above, the specification of which:

- is attached hereto.
- was filed on 13 April 1999 in the PCT/US/RO under International Serial No. PCT/US99/08087.
- said application having been amended on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to be material to the patentability of this application in accordance with 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a-d) of any **foreign application(s)** for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of any application on which priority is claimed:

Priority Claimed (If X'd)	Country	Serial Number	Date Filed
---------------------------------	---------	---------------	------------

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to be material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Serial Number	Date Filed	Patented/Pending/Abandoned
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

Serial Number	Date Filed
<u>60/081,506</u>	<u>13 April 1998</u>
_____	_____

I hereby appoint the following persons of the firm of **WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS LLP**, One Liberty Place - 46th Floor, Philadelphia, Pennsylvania 19103 as attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Mark DeLuca Reg. No. 33,229

Michael P. Dunnam Reg. No. 32,611

Joseph R. Condo Reg. No. 42,431

Address all telephone calls and correspondence to:

Mark DeLuca / Michael P. Dunnam / Joseph R. Condo
WOODCOCK WASHBURN KURTZ
MACKIEWICZ & NORRIS LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone No.: **(215) 568-3100**
Facsimile No.: **(215) 568-3439**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name: David C. ALSOP	 Signature
Mailing Address: 29 Wheeler Road Newton, MA 02459 MA USA	Date of Signature: <u>9/25/00</u>
City/State of Actual Residence: Newton, Massachusetts	Citizenship: <u>US</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**In Re Application of:**

David C. Alsop

International Application No: PCT/US99/08087 **Group Art Unit:** not yet known**International Filing Date:** 13 April 1999**Examiner:** not yet assigned**For:** MULTI-SLICE CEREBRAL BLOOD
FLOW IMAGING WITH CONTINUOUS
ARTERIAL SPIN LABELING MRIAssistant Commissioner for Patents
Washington DC 20231
ATTN: BOX PCT

Sir:

ASSOCIATE POWER OF ATTORNEYThe undersigned, of the firm WOODCOCK WASHBURN KURTZ
MACKIEWICZ & NORRIS LLP, One Liberty Place - 46th Floor, Philadelphia, Pennsylvania
19103, Attorney and/or Agents for Applicant(s), hereby appoints the following:


Robert B. Washburn	Registration No. <u>16,574</u>	David A. Cherry	Registration No. 35,099
Richard E. Kurtz	Registration No. <u>19,263</u>	Terence P. Strobaugh	Registration No. 25,460
John J. Mackiewicz	Registration No. <u>19,709</u>	Lynn A. Malinoski	Registration No. 38,788
Norman L. Norris	Registration No. <u>24,196</u>	Michael J. Swope	Registration No. 38,041
Dale M. Heist	Registration No. <u>28,425</u>	Michael J. Bonella	Registration No. 41,628
John W. Caldwell	Registration No. <u>28,937</u>	Harold H. Fullmer	Registration No. 42,560
Gary H. Levin	Registration No. <u>28,734</u>	William R. Richter	Registration No. 43,879
Steven J. Rocci	Registration No. <u>30,489</u>	John E. McGlynn	Registration No. 42,863
Dianne B. Elderkin	Registration No. <u>28,598</u>	Kimberly R. Hild	Registration No. 39,224
John P. Donohue, Jr.	Registration No. <u>29,916</u>	Jonathan M. Waldman	Registration No. 40,861
Henrik D. Parker	Registration No. <u>31,863</u>	Chad Ziegler	Registration No. 44,273
Suzanne E. Miller	Registration No. <u>32,279</u>	Gwilym J.O. Attwell	Registration No. 45,449
Lynn B. Morreale	Registration No. <u>32,842</u>	David N. Farsiou	Registration No. 44,104
Mark DeLuca	Registration No. <u>33,229</u>	Paul K. Legaard	Registration No. 38,534
Joseph Lucci	Registration No. <u>33,307</u>	Maureen S. Gibbons	Registration No. 44,121
Michael P. Dunnam	Registration No. <u>32,611</u>	Steven H. Meyer	Registration No. 37,189
Michael D. Stein	Registration No. <u>34,734</u>	Paul B. Milcetic	Registration No. P46,261
Albert J. Marcellino	Registration No. <u>34,664</u>	Michael K. Jones	Registration No. 41,100
David R. Bailey	Registration No. <u>35,057</u>	Frank T. Carroll	Registration No. 42,392
Doreen Yatko Trujillo	Registration No. <u>35,719</u>	Hans J. Crosby	Registration No. 44,634
Barbara L. Mullin	Registration No. <u>38,250</u>	Mark J. Rosen	Registration No. 39,822
Kevin M. Flannery	Registration No. <u>35,871</u>	Mitchell R. Brustein	Registration No. 38,394
Michael P. Straher	Registration No. <u>38,325</u>	Eric H. Vance	Registration No. P47,151

Peter M. Ullman	Registration No. <u>43,963</u>	Christine A. Goddard	Registration No. <u>P46,731</u>
Thomas E. Watson	Registration No. <u>43,243</u>	Gregory L. Hillyer	Registration No. <u>44,154</u>
Richard B. LeBlanc	Registration No. <u>39,495</u>	Patrick J. Farley	Registration No. <u>42,524</u>
Joseph D. Rossi	Registration No. <u>47,039</u>	Ellen M. Klann	Registration No. <u>44,836</u>
George J. Awad	Registration No. <u>P46,528</u>	Steven B. Samuels	Registration No. <u>37,711</u>
Steven D. Maslowski	Registration No. <u>P46,905</u>	Susan C. Murphy	Registration No. <u>46,221</u>
S. Maurice Valla	Registration No. <u>43,966</u>		
Vincent J. Roccia	Registration No. <u>43,887</u>		
Robin S. Quartin	Registration No. <u>45,028</u>		
Maria M. Kourtakis	Registration No. <u>41,126</u>		

his/her associates with full power to prosecute the above-identified application and to transact all business in the Patent Office connected therewith and requests that correspondence continue to be directed to the firm of WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS LLP at the above address.

Date:

10/10/00




Joseph R. Condo
Registration No. 42,431

Woodcock Washburn Kurtz
Mackiewicz & Norris LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 1997 WWKMN

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



GPO 2009 O - 960

Application deficiencies were found during scanning:

- Page(s) _____ of _____ were not present:
for scanning. (Document title)
- Page(s) _____ of _____ were not present:
for scanning. (Document title)
- Scanned copy is best available. Drawings